Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G
Executive Summary
Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.
You may also be interested in...
Talking ATTD, 780G, Rumors And Missteps With Medtronic’s Diabetes Leaders
Medtech Insight spoke to the president of Medtronic’s diabetes business, Que Dallara, as well as two of the company’s medical affairs directors, about the company’s recently published data, and the timeline for the US launch of its 780G system.
News We're Watching: Renal Denervation Trial Highlights, TAP Pilot Update, Cardiohelp Safety Alert
Two new studies support ReCor’s Radiance Ultrasound Renal Denervation System, and renal denervation also won the backing of European medical societies. Additionally, the FDA issued an update on the Total Product Life Cycle Advisory Program (TAP) “soft” pilot, and a disposable component of the Getinge/Maquet Cardiohelp system was flagged for possible sterility issues.
UK To Fund ‘Artificial Pancreas’ Technology, But Only For Companies That Cut Prices
The UK’s health technology assessment organization is in favor of funding hybrid closed loop systems for certain people with type 1 diabetes, but only if companies agree to provide such products at more “cost-effective” prices.